Abstract
Objective: Recurrent epithelial ovarian cancer (EOC) is associated with significant mortality and a median survival rate of only 12–18 months. Disease recurrence is common in these patients, and most of them eventually develop platinum-resistant or refractory disease. Unfortunately, over the past 20 years the prognosis of EOC has not improved. This is due in large part to the presence of chemoresistant cancer stem cells (CSCs) that contribute to tumor propagation, maintenance, and treatment resistance. We are using ChemoID, a CLIA-certified and CAP-accredited drug response assay to identify the most effective chemotherapy treatment against CSCs and bulk of tumor cells from of a panel of chemotherapies, offering great promise for individualized cancer management.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
